Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $12.72, but opened at $12.23. Ginkgo Bioworks shares last traded at $11.85, with a volume of 209,900 shares changing hands.
Ginkgo Bioworks Price Performance
The company's fifty day moving average is $8.64 and its two-hundred day moving average is $9.14.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The company had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. Analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.
Institutional Trading of Ginkgo Bioworks
Institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. lifted its position in shares of Ginkgo Bioworks by 25.4% in the first quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock valued at $3,915,000 after acquiring an additional 139,126 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Ginkgo Bioworks during the first quarter worth about $120,000. Millennium Management LLC grew its stake in shares of Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock valued at $8,137,000 after buying an additional 757,535 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Ginkgo Bioworks by 322.6% in the first quarter. AQR Capital Management LLC now owns 158,939 shares of the company's stock valued at $906,000 after buying an additional 121,326 shares in the last quarter. Finally, PDT Partners LLC grew its stake in shares of Ginkgo Bioworks by 104.0% in the first quarter. PDT Partners LLC now owns 385,153 shares of the company's stock valued at $2,195,000 after buying an additional 196,350 shares in the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Articles
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
